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Breast
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for Breast Implant Illness in 248 Patients
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ABSTRACT
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Background: Breast implant illness (BII) is a term popularized by social media to
describe systemic symptoms that patients ascribe to their breast implants. Though
the concept of implants as an underlying cause for a systemic illness remains controversial, few studies have delineated the implant characteristics, capsular histology, and outcomes of patients who undergo explantation for BII.
Methods: We retrospectively reviewed the demographics, presenting symptoms,
outcomes, capsular histology, and culture results of all women who presented to
the senior author with symptoms attributed to BII and underwent breast implant
removal with capsulectomy from August 2016 to February 2020. Chi-square and
logistic regression analyses were performed to evaluate association between
implant type, composition, and findings of inflammation on capsule pathology.
Results: Among 248 patients, 111 (23%) capsules demonstrated inflammatory
changes on permanent pathology. Capsular inflammation was independently associated with silicone versus saline (right odds ratio [OR] = 2.18 [1.16–4.11], P = 0.016,
left OR = 2.35 [1.08–5.12], P = 0.03) and textured versus smooth implants (right
OR = 2.18 [1.16–4.11], P = 0.016, left OR = 2.25 [1.17–4.31], P = 0.01). Silicone
material was present in the capsules of 12 patients (4.8%). Fourteen patients had
positive cultures. There was one pneumothorax (0.4%), three hematomas requiring evacuation (1%), and two DVTs (0.8%). Of 228 patients, 206 (90.4%) reported
high satisfaction with the outcome of the procedure.
Conclusions: In a large cohort of BII patients, we found that capsular inflammation
is significantly associated with silicone and textured implants. Implant removal with
capsulectomy can be safely performed in patients with BII with a low complication
rate and high patient satisfaction. (Plast Reconstr Surg Glob Open 2021;9:e3813; doi:
10.1097/GOX.0000000000003813; Published online 7 September 2021.)

INTRODUCTION

Breast implant illness (BII) is a novel description
for a constellation of symptoms potentially driven by a
poorly characterized immune or biochemical response
to breast implants.1,2 The name for this disease process has been coined by women who believe they have
From the *Department of Surgery, Abington-Jefferson Health,
Abington, Pa.; †Division of Plastic and Reconstructive Surgery,
Temple University Hospital, Philadelphia, Pa.; ‡Buinewicz Plastic
Surgery, Doylestown, Pa.; and §Department of Clinical Sciences,
Lewis Katz School of Medicine, Temple University, Philadelphia, Pa.
Received for publication March 22, 2021; accepted July 19, 2021.
Presented at the American Society of Plastic Surgeons, Virtual
Plastic Surgery Meeting, October 16–18, 2020; and at the Robert
H. Ivy Society of Plastic Surgery, Annual Virtual Scientific Meeting,
November 7, 2020.
Copyright © 2021 The Authors. Published by Wolters Kluwer Health,
Inc. on behalf of The American Society of Plastic Surgeons. This
is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible to download and share the
work provided it is properly cited. The work cannot be changed in
any way or used commercially without permission from the journal.
DOI: 10.1097/GOX.0000000000003813

become ill from their implants rather than by a medical professional society. Awareness of BII is increasingly
fueled by the power of social media, with one recent
study reporting an online group that reached nearly
110,000 members.3,4 BII symptoms are frequently nonspecific, vary in severity, and can affect nearly all organ
systems, characteristics which have been noted to overlap with many somatization disorders.5–7 Despite growing concern among the general public regarding BII,
breast augmentation is on the rise, with nearly 330,000
procedures performed in 2018 (a 15% increase from
2014), and national data show ongoing trends favoring
implant-based breast reconstruction.8,9 The leading professional societies in plastic surgery have hosted several
panels to discuss BII, and continue to offer forums to
facilitate dialog among patients, patient advocates, and
surgeons.10–12
There is a paucity of knowledge about the possible pathophysiology of BII, and many prior studies of implants and
systemic disease have occurred in nonsurgical fields with controversial conclusions.2,6,13–18 Treatment recommendations
Disclosure: The authors have no financial interest to declare
in relation to the content of this article.
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for this patient group can vary widely, with nearly all surgeons advocating frank and even-handed discussion with
patients in light of strong evidence supporting the safety
of implants,14,19 but disagreeing whether surgical treatment
including explantation and capsulectomy should be offered
for symptoms of uncertain etiology.2,4,20 We sought to better
characterize the presenting symptomatology, postoperative
outcomes, patient satisfaction, and capsular findings of a
population of patients who self-identified as having BII and
proceeded to undergo removal of their implants combined
with excision of the associated implant capsule.

METHODS

This study was conducted after receiving approval
from the hospital institutional review board at Abington
Hospital-Jefferson Health with a waiver of the need for
individual consent (IRB#19-039). We retrospectively
reviewed the medical records of all women 18 years of age
and older who presented to the senior author from 2016
to 2020 with systemic symptoms that patients ascribed to
their breast implants and subsequently underwent total
capsulectomy and implant removal after appropriately
balanced discussion of expectations, risks, and the current
scientific evidence.
Patients underwent explantation via previous inframammary, mastectomy, or periareolar incisions when
possible, or through concurrent mastopexy if being performed. Bilateral capsulectomies were performed and cultures were routinely obtained intraoperatively through a
capsulotomy made to access the implant pocket. A portion
of the capsule was divided and submitted for permanent
pathology.
Data obtained from medical records included demographics, indication for initial placement of implants
(reconstruction versus cosmetic), medical history, physical examination findings, presenting symptoms, results of
any laboratory tests obtained, operative findings at time
of surgery, simultaneous procedures, and postoperative
follow-up. The senior author obtained cultures from all
implant pockets before excision of the capsule. The first
four postoperative visit notes were reviewed to determine
each patient’s level of satisfaction with the results of the
procedure and specific postoperative symptoms when
available, with a mean follow-up of 6 months.
Statistical analysis was performed using SAS 9.4 (SAS
Institute, Cary, N.C.). Chi-squared analysis was utilized for
independent variables, and logistic regression analysis was
used to evaluate implant characteristics associated with
findings of inflammation on pathology, which was defined
as calcification or microcalcifications, histiocytic reaction
or abundance of histiocytes, macrophages, or giant cells,
presence of sclerosis, lymphoid or lymphocytic infiltration, or the term inflammation otherwise contained in the
final pathology report with reference to the capsule.

RESULTS

A total of 248 patients underwent bilateral implant
removal with capsulectomy performed by the senior
author from August 2016 to February 2020. Two hundred
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and twenty-six patients (93%) had implants placed for cosmetic purposes. The median patient age at presentation
was 45 years (range: 22–72 y), median age at placement of
first implants was 29.5 and average BMI was 24. On physical examination, 130 patients (55%) exhibited Baker II
and 95 patients (39%) exhibited Baker III/IV capsular
contracture at initial presentation. Patient characteristics
are summarized in Table 1.
The most common symptoms mentioned at time of
initial evaluation included generalized pain, fatigue, cognitive “fogginess,” migraines, headaches, anxiety, arthritis,
vision changes, dyspnea, hair loss, weight gain, back pain,
rashes, generalized gastrointestinal issues, and depression. The number of complaints did not vary significantly
between types of implants. Symptoms are summarized in
Figure 1.
Operative details and findings are shown in Table 2.
Simultaneous procedures at time of implant removal and
total capsulectomy included mastopexy in 53 patients
(21%), scar revision in 12 patients (4.9%), breast reconstruction in five patients (2.0%), and abdominoplasty
in one patient (0.4%). One patient requested implant
replacement of her silicone implants with saline implants
combined with capsulectomy (0.4%). Implant rupture at
time of explantation was noted in 20 patients on the right
(8.2%), and 18 patients on the left (7.4%). Two hundred
forty-four patients (98.3%) underwent total capsulectomy
on the right and 245 patients (98.7%) had total capsulectomy on the left. Two patients had a partial excision of the
Table 1. Patient Characteristics
Average age at presentation (y)
Average age at placement of breast implants (y)
Average BMI
Reason for implant placement
Cosmetic
Reconstructive
Current smoker
Diabetes
Grade of capsular contracture
I
II
III
IV
Autoimmune diagnosis
Arthritis
Chronic inflammatory response syndrome (CIRS)
Lupus
Sjogren’s syndrome
Raynaud’s sydrome
Graves disease
Hashimoto’s thyroiditis
Scleroderma
Multiple sclerosis
Ulcerative colitis
Crohn’s disease
History of breast cancer
History of other cancer
Anxiety
History of panic attacks
Depression
Suicidal ideation
Fibromyalgia
Irritable bowel syndrome
Mild anemia (hemoglobin 11–11.9 g/dL)
Moderate anemia (hemoglobin 8.0–10.9 g/dL)
Leukopenia (WBC < 4.5 × 109/L)
Elevated alkaline phosphatase (>130 U/L)

44
31
24
226 (93%)
18 (7%)
19 (8.4%)
7 (2.8%)
11 (4.7%)
122 (52%)
60 (25%)
43 (18%)
67 (27%)
3 (1.2%)
10 (3%)
3 (1.2%)
10 (4%)
2 (0.8%)
20 (8.1%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
1 (0.4%)
10 (4%)
17 (6.9%)
79 (32%)
10 (4%)
38 (15%)
1 (0.4%)
17 (6.9%)
23 (9.3%)
2 (0.8%)
2 (0.8%)
7 (3%)
3 (1.2%)
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Fig. 1. Most common complaints reported by patients on initial evaluation.

capsules bilaterally, and one patient had no capsulectomy
performed. The capsules were removed intact in 27 patients
(10.8%) on the right and 28 patients (11.2%) on the left.
There were six major complications, which consisted of
one pneumothorax that required hospital admission for
observation, three breast hematomas that required evacuation in the odds ratio (OR), and two deep vein thromboses
that were managed with anticoagulation. Minor complications consisted of five delayed seromas and three liquified hematomas which were treated by aspiration. Three
patients who underwent simultaneous mastopexies had a
suture infection which was treated with antibiotics.
Ninety-eight patients (40.2%) had silicone implants,
and 146 (59.8%) had saline implants. Silicone implants
included 38 Allergan silicone (21%), 32 Mentor silicone
(18%), and six Sientra silicone (3%). Saline implants
included 71 Mentor saline (39%), 34 Allergan saline
(19%), and one IDEAL saline (0.6%). In 63 patients, the

Table 2. Operative Details
Incision Type
Previous mastectomy
Inframammary
Mastopexy
Periareolar
Additional procedures performed
Mastopexy
Scar revision
Implant rupture
Right
Left
Total capsule excision
Right
Left
Capsule removed intact
Right
Left

15 (6%)
173 (70%)
57 (23%)
3 (1.2%)
53 (21%)
12 (4.8%)
20 (8.2%)
18 (7.38%)
244 (98.3%)
245 (98.7%)
27 (10.8%)
28 (11.2%)

brand of implant could not be determined. Two hundred
and seven patients (85%) had smooth implants, and 37
(15%) had textured implants (Fig. 2).
All capsules were submitted to permanent pathology,
and 111 (23%) of the capsules were found to have evidence of acute or chronic inflammation. One capsule
did have atypical lymphocytic infiltration but was CD30
negative in testing for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Positive cultures
were noted in fourteen patients, eight (3.28%) from right
breast pockets, and nine (3.69%) from left breast pockets. The most common organisms from cultures included
several strains of Staphylococcus as shown in Table 3. One
patient had cultures positive for Candida albicans from
both breast pockets and underwent a 2-week course of
fluconazole after consultation with an infectious disease
specialist but had an otherwise uneventful postoperative
course. Twelve patients (4.9%) had capsular findings of
“refractile/nonpolarizable foreign material or silicone.”
Of these patients, three had bilateral implant rupture,
four had one ruptured and one unruptured implant, and
five had no evidence of rupture. All of these patients had
histiocytic reactive changes, macrophages, or multinucleated cells associated with the refractile material on histology. Four of these patients had saline implants and eight
had silicone implants at time of explantation (Table 4).
Capsular inflammation was significantly associated
with silicone implants vs. saline implants (right: 31.3%
silicone versus saline 16.4%, P = 0.007; left: 29.9% silicone
versus 15.1% saline, P = 0.005). Additionally, inflammation was significantly associated with textured implants
versus smooth implants (right: 38.9% textured versus
19.9% smooth, P = 0.01; left: 37.8% textured versus 18.5%
smooth, P = 0.008). Figure 3 shows rates of inflammation
by implant type.
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Fig. 2. Characteristics of removed implants. A, Make and model. B, Texture and fill.

On logistic regression modeling, capsular inflammation was independently associated with silicone versus saline (right: OR = 2.18 [1.16–4.11], P = 0.016, Left:
OR = 2.25 [1.17–4.31], P = 0.015) and textured versus
smooth implants (right: OR = 2.26 [1.04–4.9], P = 0.040,
left: OR = 2.35 [1.08–5.12], P = 0.031) (Fig. 4). Textured
and silicone characteristics independently increased inflammation when present together to approximately 51% but
had an additive rather than synergistic effect on increasing
inflammation.
The average number of follow-up visits was 3.9 ± 2.1,
with a duration of 1.8–6 months. Postoperative visit notes
addressed specific symptoms in 46 patients, and of these,
44 (96%) reported a decrease in the number of symptoms
after surgery. Of 228 patients reporting their level of satisfaction with the procedure at first postoperative visit,
206 (90.4%) reported they were satisfied with the results
and had no or minor complaints. In subsequent follow-up
visits, 125 of 153 (81.7%) patients reported high satisfaction at their second postoperative visit, 59 of 75 (78.7%)
reported high satisfaction at their third postoperative visits, and 30 of 39 (77%) reported high satisfaction at the
fourth postoperative visit.
Table 3. Classification of Culture Results
Organism
Staphylococcus epidermidis
Staphylococcus capitis
Staphylococcus lugdunensis
Unspecified: coagulase (−) Staphylococcus
Unspecified: gram (+) cocci
Unspecified: Bacillus sp.
Unspecified: Propionibacterium sp.
Unspecified: few mixed skin flora
Cutibacterium acnes
Candida albicans
Unspecified: gram (+) rods
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No. Positive
Cultures
2
3
1
2
1
2
1
1
1
2
1

DISCUSSION
Brief History of the BII Controversy

The association of breast implants with autoimmune
or systemic symptoms is an ongoing, heavily debated topic.
Despite early reports of patients with silicone implants
developing an immunoadjuvant disease,21–23 large retrospective studies comparing incidence of autoimmune
diseases in women with silicone implants found no association, a finding confirmed by a special committee of the
Institute of Medicine in 1999.19,24–27 This ultimately resulted
in lifting the FDA moratorium on silicone implants but
has by no means put an end to the controversy surrounding implant-related systemic illness. In recent years, an
increasingly large number of women with prominent
social media presence are seeking implant removal for a
constellation of nonspecific systemic symptoms referred
to as BII. A recent review by Magnusson et al2 suggests
that efforts at scientific investigation of an underlying
pathophysiology for these symptoms have unfortunately
been hampered by misrepresentation in the media and
an excessive focus on litigation. The pathogenesis of an
immunoadjuvant disease process associated with breast
implants has been contested in the literature for decades,
with several rheumatology studies stipulating a direct effect
of silicone in biochemically altering metabolic or cellular
processes,13,22,28,29 whereas others argue that the constellation of somatic symptoms ascribed to implants may be the
result of disrupted pain processing pathways leading to
psychological distress in a manner similar to disorders like
fibromyalgia.5,30 The relation of either these hypotheses
to BII remains unclear at the present time; however, an
important question to address is whether implant removal
and excision of the associated capsule as many BII patients
specifically request is associated with consistent symptom improvement and postoperative satisfaction. To this
end, we sought to characterize the presenting symptoms,
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Table 4. Patients with Findings of Nonpolarizable Refractile Material or Silicone on Pathology
Laterality of
Capsular Pathology
Right
Right
Right
Bilateral
Bilateral
Bilateral
Bilateral
Bilateral
Bilateral
Bilateral
Bilateral
Bilateral

Laterality of
Implant Rupture
Bilateral
Right
N/A
Right
N/A
N/A
N/A
Bilateral
Bilateral
Left
Left
N/A

Implant
Make

Implant
Model

Allergan
Allergan
Allergan
N/A
Mentor
Allergan
Allergan
N/A
N/A
N/A
N/A
Mentor

demographics, outcomes, and implant and capsular findings of a large cohort of BII patients who presented to the
senior author and ultimately elected to undergo implant
removal with total capsulectomy.
Presenting Symptoms, Postoperative Outcomes, and Patient
Satisfaction

In our cohort of patients, we found that preoperatively
the most common presenting symptoms were nonspecific
somatic complaints such as generalized pain (163 patients,
67%) and fatigue (133 patients, 55%). This characterizes
the difficulty of defining BII as an entity, as complaints
are frequently nonspecific and highly subjective in nature,
a theme which is shared with reports of immunoadjuvant disease related to silicone implants in the past. We
found that in 46 patients who had postoperative follow-up
addressing specific symptoms, 44 patients (96%) reported
overall improvement. Previous explantation studies have
noted substantial symptomatic improvement in patients
who did not meet laboratory or diagnostic criteria for
known autoimmune disorders, such as the study by De
Boer et al30 which reviewed 23 published case series and
reports from 1960 to 2016 and found that nearly 75%

Saline
Silicone
Saline
Silicone
Saline
Saline
Silicone
Silicone
Silicone
Silicone
Silicone
Silicone

Implant
Composition

Capsular
Culture

Textured
Smooth
Textured
Smooth
Smooth
Smooth
Textured
Textured
Textured
Textured
Textured
Textured

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

of patients reported symptomatic improvement after
removal of their silicone implants. Rohrich et al31 noted
that a higher number of musculoskeletal complaints were
associated with higher likelihood of improvement in 38
patients with silicone implants who underwent explantation. In the largest retrospective study of explantation in
BII patients to date, Wee et al32 found sustained improvement across 11 symptom domains, which encompassed
cognitive, musculoskeletal, and systemic symptoms in 752
patients which was maintained after 30 postoperative days.
Interestingly, the authors of this recent study found similar symptom improvement with removal of both silicone
and saline implants, and did not observe a difference
in patient self-reported outcomes between patients with
textured or smooth implants.32 One of the difficulties in
monitoring symptom improvement in BII patients is the
duration of follow-up, as many patients are frequently selfreferred over a potentially large geographic area and have
limited follow-up with their surgeon unless postoperative
complications arise. Therefore, it is difficult to address
the frequency of symptom recurrence or the success of
implant removal in the long term, and previous studies
of BII have largely been limited to studying outcomes in

Fig. 3. Rates of inflammation by implant type. A, implant fill. B, implant texture.
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Fig. 4. Logistic regression modeling for ORs with regards to texturing and implant fill.

the first 6 months.32,33 In two older explantation studies
for patients who complained of systemic symptoms, an
initial period of symptom improvement was followed by
recurrence when longer duration follow-up was available.
Slavin and Goldwyn34 found that in eight patients who
underwent implant removal with systemic complaints,
only one of eight patients had sustained improvement
after 2.5 years of follow-up. The study was notably limited
by the relatively small number of patients with symptoms
that fit the pattern of BII, with the majority of patients
requesting explantation either from fear of harmful consequences or aesthetic reasons. Godfrey and Godfrey20
found that in 37 women who underwent explantation
followed by autologous breast reconstruction, although
33 had initial improvement 1 month postoperatively, 21
patients had relapse of symptoms by 6 months, and only
seven patients reported improvement by 12-month followup. Although these prior explantation studies included a
subset of women with ostensibly systemic symptoms, evaluation of outcomes was limited by including patients who
underwent implant removal due to local symptoms related
to contracture, anxiety about implants due to the silicone
controversy of the 1990s, or explantation for older generation implants that had a higher rate of rupture and leakage.20,31,35–38 Additionally, previous studies largely focused
on patients with silicone implants in light of the FDA moratorium, whereas the majority (59.8%) of patients in our
study had saline implants.
We observed a relatively low complication rate in our
practice of implant removal and capsulectomy, with six of
248 (2.4%) patients having a major complication defined
as pneumothorax, hematoma requiring evacuation, or
DVT, and eight of 248 (4.4%) patients having a minor
complication defined as seroma, liquefied hematoma, or
wound infection. Other than the singular complication of
pneumothorax, it is difficult to ascribe any particular complication to addition of capsulectomy to the procedure.
Though the addition of capsulectomy is controversial for
asymptomatic patients undergoing removal of textured
implants for future concern of BII or BIA-ALCL,15 a large
number of BII patients including our cohort also have a

6

high rate of capsular contracture, and addition of capsulectomy may lead to a more substantial symptom improvement of local musculoskeletal symptoms.32 A prior small
retrospective controlled study by Kappel and Pruijn39
found a more pronounced improvement in systemic
symptoms when capsulectomy was added to the implant
removal procedure.
Inflammation on Capsular Histology

We found that acute or chronic inflammation was
present in 111 (23%) of capsules on permanent pathology, and there was a significant association with silicone
and textured implants. Chronic inflammation in the form
of calcification surrounding implants has been found
to correlate with implant shell thickness, duration after
placement, and integrity of the shell in prior studies, and
although more frequently associated with older generation silicone implants, has been associated with the elastomer shell of saline implants as well.40–42 Additionally, small
amounts of silicone in the capsule outside an otherwise
intact implant shell have been found to induce chronic
inflammation by uptake into macrophages, subsequently
triggering cytokine production and fibroblast activity.43,44
Though we found evidence of this “silicone bleed” phenomenon in five patients with unruptured implants, the
clinical relation to BII is currently not understood, as only
a small subset of patients in our study demonstrated capsular inflammation on histology or findings of silicone
material. The pathogenesis of BII remains largely hypothetical, as no consistent rheumatologic, histologic, or
microbiological finding has substantiated a clear underlying pathophysiology for the condition. In light of some
promising recent studies such as that by Lee et al,33 we
speculate that textured implants may be associated with
more inflammation due to increased propensity for biofilm formation, which may be difficult to detect by routine bacterial cultures. Moreover, Wee et al32 found that
patients with capsular contracture had a significantly
greater self-reported improvement after explantation.
Though this could partially attest to the mechanical
nature of some symptoms such as chest wall restriction,

Katsnelson et al. • Implant Removal and Capsulectomy for BII
the association with improvement in more nebulous symptoms such as fatigue and cognitive problems could also
suggest a shared inflammatory pathogenesis between capsular contractures and BII.
Culture Results

Fourteen patients in our cohort had positive culture
results, including eight patients with positive cultures of the
right breast pocket and nine with positive cultures of the
left breast pocket (3.69%). The most common organisms
were strains of Staphlyococcus (47%), which is consistent with
cultures of prior studies of periprosthetic implant colonization such as the study by Peters et al,45 which evaluated
the implants and capsules of 100 women who had silicone
implants removed between 1992 and 1995. Their group
found 42% of the capsules were colonized with bacteria
and 25% were heavily calcified suggesting chronic inflammation.45 Though the clinical relevance of these positive
cultures to BII is currently unknown, Lee et al33 recently
compared microbiological data between 50 patients
undergoing explantation and capsulectomy for BII with
a control group that underwent implant exchange, finding that the BII group had a six-fold higher rate of positive
cultures. The most common organisms they reported were
Propionbacterium acnes in 24% of the BII group, followed by
Staphylococcus epidermidis in 6%. Cultures were obtained by
grinding a portion of the divided capsule sent directly for
microbiological analysis as well as part of the implant shell,
a method which may have a greater yield for detection
of microorganisms within a biofilm structure compared
to the routine cultures obtained in our study, and these
elaborate methods merit further investigation to elucidate
the role of a potential indolent infection as a cause for BII.
Our study is limited by its retrospective nature and lack
of standard documentation, without which we were unable
to evaluate changes in specific symptoms after explantation
or correlate capsular findings on pathology with symptom
severity preoperatively. Like prior studies of explantation
as a treatment for patients presenting with systemic symptoms, our study is additionally challenged by the subjective
bias of defining BII symptoms, lack of a control group, and
selection bias as patients were predominantly self-referred
to our office for explantation. Follow-up duration was also
a mean of 6 months, which limits our ability to predict
long-term symptom resolution or recurrence.
Nonetheless, we found that evidence of acute or
chronic inflammation was significantly more common in
silicone compared to saline and textured compared to
smooth implants. This interesting finding potentially suggests an association between a specific implant composition and development of symptoms described as BII. We
also found that implant removal with capsulectomy had
a low complication rate, and that the majority of patients
expressed satisfaction with their postoperative outcomes
as well as improvement in their overall symptoms during the follow-up period. Building on the results of our
retrospective study, we are currently conducting a prospective study focusing on standardized comparison of
preoperative symptoms and postoperative improvement

to determine which patients would most likely benefit
from implant removal and capsulectomy.

CONCLUSION

Our data suggest that in a subset of patients presenting
with BII symptoms, there is an underlying inflammatory
response associated with the implant capsule, a response
which appears to be more common in silicone versus
saline and textured versus smooth implants. This response
may be associated with symptoms of BII. More research is
necessary to further elucidate the underlying process fueling BII; however, in this study, we have demonstrated that
implant removal with total capsulectomy can be safely performed in the BII population with minimal complications
and high patient satisfaction.
Jacob Y. Katsnelson, MD
Department of Surgery
Abington Hospital-Jefferson Health
1200 Old York Road
Price Medical Office Building, Suite 604
Abington, PA 19001
E-mail: jacob.katsnelson@jefferson.edu
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